Clinical trials: Pancreatic Adenocarcinoma Locally Advanced
Head and Neck Carcinoma, Adenoid Cystic Carcinoma
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non…
- Conditions
- Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT03556228
- Testing
- VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg)
- Where
- 13 sites in United States, Puerto Rico
- Volunteers
- 242 people
- Sponsor
- VM Oncology, LLC
Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
Phase I - Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, and a Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Non-operable Adenocarcinoma of the Pancreas
Phase 0 - Open label, Single dose study of siG12D LODER in Patients with operable adenocarcinoma of the pancreas. The primary endpoint: To assess efficacy and local distribution of siRNA out of eight high dose siG12D LODERs in…
- Trial name
- NCT01188785
- Testing
- siG12D LODER
- Where
- 3 sites in Israel
- Volunteers
- 15 people
- Sponsor
- Silenseed Ltd
Solid Tumor, Colorectal Cancer
Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors
This is a phase 1 multi-center, open-label study evaluating IBI3028 Treatment in participants with locally advanced, unresectable, or metastatic solid tumors
- Conditions
- Solid Tumor, Colorectal Cancer, Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT07589205
- Testing
- Drug: IBI3028
- Where
- China
- Volunteers
- 493 people
- Sponsor
- Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Neoplasms, Colorectal Neoplasms
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
This study will evaluate the efficacy and safety of alectinib in participants with Anaplastic Lymphoma Kinase (ALK)-positive locally advanced or metastatic solid tumors other than lung cancer.
- Conditions
- Neoplasms, Colorectal Neoplasms, Melanoma, Pancreatic Neoplasms
- Trial name
- ALpha-T (NCT04644315)
- Testing
- Alectinib
- Where
- 29 sites in United States
- Volunteers
- 1 people
- Sponsor
- Hoffmann-La Roche
Locally Advanced Pancreatic Adenocarcinoma
OncoSil Pancreatic Cancer Post-marketing Clinical Registry - Italy
The OSPRItaly Patient Registry has been developed to assess the performance and safety of the OncoSil™ device when used within the approved indication of unresectable, locally advanced pancreatic cancer, in combination with…
- Trial name
- OSPRItaly (NCT06399172)
- Testing
- OncoSil
- Volunteers
- 50 people
- Sponsor
- OncoSil Medical Limited
Pancreatic Neoplasms, Solid Tumors
Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder
This study is open to adults with advanced cancer in the biliary tract, pancreas, lung, or bladder. This is a study for people for whom previous treatment was not successful or no treatment exists.
- Conditions
- Pancreatic Neoplasms, Solid Tumors, Biliary Tract Cancer, Lung Neoplasms
- Trial name
- NCT05512377
- Testing
- Brigimadlin
- Where
- 60 sites in United States, Australia and 14 more
- Volunteers
- 99 people
- Sponsor
- Boehringer Ingelheim
Metastatic Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma
Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients.
An open-label dose escalating phase Ib study of SCO-101 in combination with gemcitabine and nab-paclitaxel. The primary objectives are to establish the safety profile and the MTD of SCO-101 when combined with gemcitabine and…
- Conditions
- Metastatic Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Inoperable Disease, Localized Pancreatic Adenocarcinoma
- Trial name
- PANTAX-Ib (NCT04652206)
- Testing
- SCO-101, Gemcitabine, Nab paclitaxel
- Where
- 4 sites in Denmark, Germany
- Volunteers
- 18 people
- Sponsor
- Scandion Oncology A/S
Stage III Pancreatic Cancer
A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer
Subjects will be offered the opportunity to participate in a randomized, controlled, 2-arm, unblinded multicenter trial (RCT). There will be 2 study arms: the control arm receiving chemotherapy with the modified FOLFIRINOX…
- Trial name
- DIRECT (NCT03899636)
- Testing
- Modified FOLFIRINOX Regimen, NanoKnife System
- Where
- 6 sites in United States
- Volunteers
- 528 people
- Sponsor
- Angiodynamics, Inc.
Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
This is a nonrandomized, uncontrolled, open-label, multicenter Phase 2 study to evaluate the efficacy, safety, and tolerability of futibatinib in combination with PD-1 antibody-based SoC therapy in adult patients with solid…
- Conditions
- Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Siewert Type 1 GEJ Cancer
- Trial name
- NCT05945823
- Testing
- Futibatinib, Pembrolizumab, Cisplatin
- Where
- 22 sites in United States, France and 2 more
- Volunteers
- 53 people
- Sponsor
- Taiho Oncology, Inc.
Locally Advanced Pancreatic Adenocarcinoma
Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer
The purpose of the study is to assess the efficacy and safety of Acoustic Cluster Therapy (ACT) when given in addition to chemotherapy for treatment of Locally Advanced Pancreatic Cancer.
- Trial name
- ENACT (NCT06850623)
- Testing
- Acoustic Cluster Therapy, Modified FOLFIRINOX
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 25 people
- Sponsor
- EXACT Therapeutics AS
Metastatic Pancreatic Adenocarcinoma, Locally Advanced Unresectable Pancreatic Adenocarcinoma
Medical Food for the Dietary Management of Advanced/Metastatic Pancreatic Cancer
This is a single arm study evaluating the tolerability and markers of pancreatic cancer with a specially designed medical food restricted in specific amino acids for the dietary management of subjects with locally advanced and…
- Trial name
- NCT05078775
- Testing
- NEAAR Medical Food
- Where
- 9 sites in United States
- Volunteers
- 39 people
- Sponsor
- Faeth Therapeutics
Locally Advanced Solid Tumor
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion…
- Trial name
- NCT05732831
- Testing
- TNG462, Pembrolizumab
- Where
- 26 sites in United States, France and 1 more
- Volunteers
- 225 people
- Sponsor
- Tango Therapeutics, Inc.
Carcinoma, Pancreatic Ductal
Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02)
The purpose of the study is to evaluate a new treatment strategy for advanced pancreatic cancer disease by combining the new investigational medicinal product Atu027 with the standard chemotherapeutic gemcitabine.
- Trial name
- Atu027-I-02 (NCT01808638)
- Testing
- Atu027 & gemcitabine in lead in safety period, Atu027 & gemcitabine in treatment arm 1, Atu027 & gemcitabine in treatment arm 2
- Where
- 9 sites in Germany
- Volunteers
- 29 people
- Sponsor
- Silence Therapeutics GmbH
Pancreatic Ductal Adenocarcinoma (PDAC), Unresectable Locally Advanced
Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
This example study evaluates the safety, tolerability, and preliminary anti-tumor activity of investigational, dual-targeting chimeric antigen receptor natural killer (CAR-NK) cell products for patients with advanced pancreatic…
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Unresectable Locally Advanced, Metastatic Disease
- Trial name
- DUAL-NK-PDAC (NCT07627711)
- Testing
- EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1), EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1), Lymphodepleting chemotherapy (Flu/Cy)
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Beijing Biotech
Solid Tumor, Adult, Colorectal Cancer
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer…
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, NSCLC, Non Small Cell Lung Cancer
- Trial name
- EVEREST-2 (NCT06051695)
- Testing
- A2B694, A2B543, xT CDx with HLA-LOH Assay
- Where
- 12 sites in United States
- Volunteers
- 474 people
- Sponsor
- A2 Biotherapeutics Inc.
Locally Advanced Solid Tumor
Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion…
- Trial name
- NCT05275478
- Testing
- TNG908
- Where
- 20 sites in United States, France
- Volunteers
- 110 people
- Sponsor
- Tango Therapeutics, Inc.
Advance Solid Tumors
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of KIVU-107, a PTK7-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.
- Trial name
- NCT07229313
- Testing
- KIVU-107
- Where
- 7 sites in United States, Australia
- Volunteers
- 76 people
- Sponsor
- Kivu Bioscience Inc.
Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid tumors.
- Trial name
- NCT07488676
- Testing
- ASP546C
- Where
- 21 sites in United States, Japan
- Volunteers
- 150 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Locally Advanced Pancreatic Adenocarcinoma
Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma
Open-label, dose-escalating, Phase IIa trial of NanoPac® to treat subjects with locally advanced pancreatic adenocarcinoma via direct intratumoral injection.
- Trial name
- NCT03077685
- Testing
- NanoPac®
- Where
- 4 sites in United States
- Volunteers
- 54 people
- Sponsor
- NanOlogy, LLC
Pancreatic Ductal Adenocarcinoma (PDAC)
A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal Adenocarcinoma
The purpose of this study is to evaluate the efficacy and safety of CEND-1 in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel and placebo as first-line treatment in patients with Locally Advanced…
- Trial name
- NCT06261359
- Testing
- CEND-1, Gemcitabine, Nab paclitaxel
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.